Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective

Area of Science:

• Hepatobiliary surgery
• Interventional oncology
• Medical oncology

Background:

• Transcatheter arterial chemoembolization (TACE) is a common treatment for unresectable hepatocellular carcinoma (HCC), particularly in Japan.
• Patient populations undergoing TACE are heterogeneous, leading to a wide range of 3-year survival rates (26-47%).
• Japanese guidelines suggest TACE criteria based on tumor number/size and liver function (Child-Pugh A/B).

Purpose of the Study:

• To analyze the impact of patient selection criteria on TACE outcomes in HCC.
• To understand the variability in TACE survival rates across different patient subgroups.
• To explore potential synergistic effects of combining TACE with novel therapies.

Main Methods:

• Retrospective analysis of TACE patient data.
• Evaluation of survival rates based on tumor burden (2-3 tumors >3 cm vs. 4+ tumors) and liver function (Child-Pugh A/B).
• Review of recent studies on TACE variations and combination therapies.

Main Results:

• TACE survival rates differ significantly between Child-Pugh A and B patients, and by tumor burden.
• For Child-Pugh A patients, 3-year survival was 55% (2-3 tumors >3 cm) and 46% (4+ tumors).
• For Child-Pugh B patients, 3-year survival was 30% (2-3 tumors >3 cm) and 22% (4+ tumors).
• Newer TACE formulations and radioembolization show comparable outcomes to conventional TACE.

Conclusions:

• Patient selection and liver function are critical determinants of TACE efficacy in HCC.
• Outcomes vary significantly based on tumor characteristics and liver reserve.
• Combining TACE with molecular targeted agents may enhance survival benefits.